Showing 101-110 out of 123
Page 11 of 13« First«...910111213»
On-demand Oral Treatment With KVD900 for HAE Attacks Achieves Rapid Exposure and Improves Patient OutcomesBernstein JA, Huamin LH, Yea CM, Maetzel A, Audhya P, Williams P, Banerji A, Riedl MA
ACAAI 2021
Current management of hereditary angioedema with normal C1-inhibitor (nC1-HAE) in the United States: Results from a nationwide survey of HAE-treating physiciansRiedl MA, Danese M, Danese S, Ulloa J, and Maetzel A
EAACI 2021
Oral plasma kallikrein inhibitor KV998052 improves arterial blood oxygenation in a murine model of acute respiratory distress syndrome (ARDS)Murugesan N, Clermont AC, and Feener EP
EAACI 2021
Selective Factor XIIa inhibitor KV998083 protects mice against captopril induced vascular leakage and cleavage of high molecular weight kininogenClermont AC, Murugesan N, Edwards HJ, Whitney SA, Pethen SJ, Duckworth EJ, Hampton SL, Feener EP
EAACI 2021
Fast improvement of hereditary angioedema (HAE) attacks with the oral on-demand plasma kallikrein inhibitor KVD900: an analysis of the pharmacokinetic and pharmacodynamic profile of KVD900 and attack symptom severity during a double-blind, randomized phase 2 cross-over trial in patients with HAE type I and IIZanichelli, Andrea
C1-INHIBITOR WORKSHOP 2021
One-Time Intravitreal Injection of KVD001, a Plasma Kallikrein Inhibitor, in Patients with Central Involved Diabetic Macular Edema and Reduced Vision: An Open-Label Phase 1B StudySun JK, Maturi RK, Boyer DS, Wells JA, Gonzalez VH, Tansley R, Hernandez H, Maetzel A, Feener EP, Aiello LP.
OPHTHALMOLOGY RETINA
Rapid and nearly complete suppression of plasma kallikrein activity with the oral inhibitor KVD900: results of a phase 1 study evaluating KVD900’s potential as a treatment for acute attacks of HAEMaetzel A, Smith MD, Morten RM, Hampton SL, De Donatis GM, Murugesan NI, Rushbrooke LJ, Li L, Duckworth EJ, Feener EP, Yea C.
EAACI 2019
High plasma exposures of KVD900 achieved in First in Human study markedly inhibit plasma prekallikrein activation; early blockade of plasma kallikrein (PKa) may halt attacks in Hereditary Angioedema (HAE) by reducing contact system activation.Duckworth EJ, Hampton SL, Li L, Murugesan N, Rushbrooke L, Smith M, Morten R, Maetzel A, Yea C, and Feener EP.
C1-INHIBITOR WORKSHOP 2019
Novel oral plasma kallikrein (PKa) inhibitors KV998052 and KV998054 ameliorate VEGF-induced retinal thickening in a murine model of retinal edema.Murugesan N, Clermont AC, Pethen SJ, Li L, Duckworth EJ, Hampton SL, and Feener EP.
ARVO 2019
KVD900 as a Single Dose, Rapid, Oral Plasma Kallikrein Inhibitor for the On-Demand Treatment of Hereditary Angioedema Attacks: Pharmacokinetic and Pharmacodynamic results from a Phase 1 Single Ascending Dose Study.Hampton SL, De Donatis GM, Murugesan N, Rushbrooke LJ, Li L, Duckworth E, Smith MD, Morten RM, Maetzel A, Yea CM and Feener EP.
AAAAI 2019